The 2026 HHS peptide compounding policy describes conditional enforcement discretion for six peptide ingredients in qualifying Section 503A arrangements. It does not make the resulting drugs FDA-approved. The Federal Register calls the policy draft and nonbinding; HHS describes an interim approach while rulemaking continues. Patients still need an individual clinical assessment. Read the Federal Register notice.
Key takeaways
- Start with the exact ingredient, formulation, and route—not a broad claim that “peptides are approved.”
- Keep three questions separate: Does the arrangement qualify? What does clinical evidence show? Is it appropriate for this patient?
- Ask for a clear explanation of the pharmacy, product documentation, monitoring, and alternatives.
- Bring your health goals to a consultation; you do not need to arrive committed to a particular compound.
What changed in October and November 2026?
- October 28: The notice was filed. October 30: It was published in the Federal Register. It describes a draft, nonbinding policy pending development of the 503A bulks list. Federal Register timeline.
- November 2: LegitScript changed its certification review approach to reflect conditional allowances. This was a third-party certification change, not a drug approval. LegitScript’s announcement.
HHS describes circumstances in which it does not intend to take specified enforcement action against qualifying compounders. The notice also says the interim policy may be revisited for safety or quality issues. Read “draft” and “interim” together: neither means final FDA approval or a final bulks-list rule. Official scope and status.
Which six peptides, forms, and routes are addressed?
| Peptide | Specified form | Routes addressed |
|---|---|---|
| BPC-157 | Acetate | Subcutaneous, intramuscular, oral, topical |
| TB-500 | Acetate | Subcutaneous, intramuscular |
| Epitalon | Acetate | Subcutaneous, intramuscular; intermittent courses |
| Semax | Free base | Intranasal |
| KPV (Lys-Pro-Val) | Acetate | Oral, topical |
| MOTS-c | Acetate | Subcutaneous, intramuscular |
The ten conditions: a practical reading guide
These are headings for discussion with a clinician or compounder, not a substitute for the complete policy.
- An Appendix A ingredient.
- The specified identity and route.
- Registered sourcing and a valid COA with required testing.
- Original-manufacturer registration, manufacturing compliance, and location; intermediary validation when applicable.
- Product, serious-adverse-event, and quality-issue reporting to FDA and relevant states; patient reporting instructions.
Conditions 1–5: HHS policy, pages 2–3.
- Compounded-product labeling stating: “This is a compounded drug product. Not for resale.”
- A single active pharmaceutical ingredient (API).
- Formulation-specific human oral-bioavailability documentation for oral products.
- Only an FDA 510(k)-cleared syringe as a co-packaged or drug-containing delivery device.
- All other applicable requirements, including patient-specific prescriptions and sanitary compounding.
Conditions 6–10: LegitScript’s policy summary. LegitScript interprets the single-API condition as excluding combinations with any other active ingredient. It also explains that 503B outsourcing facilities are outside this policy’s scope.
Access, approval, and evidence answer different questions
| Question | What to ask for | What it cannot establish |
|---|---|---|
| Does this arrangement fit the policy? | Exact product and pharmacy documentation. | That a treatment works for your goal. |
| What supports a clinical claim? | Research relevant to the actual product, route, and patient group. | That another molecule or formulation has the same effects. |
| Is this appropriate for me? | An individualized discussion of options, uncertainty, and monitoring. | A guaranteed prescription or outcome. |
For example, if your concern is persistent fatigue, write down when it started, how it affects your day, and what has already been evaluated. Ask the clinician to explain the problem being addressed before discussing a particular ingredient. This keeps the consultation focused on your needs rather than a product name.
What remains unchanged: risks and unanswered questions
FDA explains that compounded drugs do not undergo its premarket review for safety, effectiveness, or quality. Contamination or an incorrect amount of active ingredient can cause serious harm; labels may also omit important information. Quality safeguards therefore deserve attention even when a policy describes conditional access. FDA’s explanation of compounded-drug risks.
This article evaluates policy scope, not the clinical evidence for six separate compounds. It makes no finding that one treats an injury, improves cognition, produces weight loss, or extends life. Those claims need their own evidence review. Ask for the research behind the specific outcome being proposed, including what remains unknown.
For broader context, see our guide to peptide legal-status questions. For documentation questions, read how to evaluate peptide quality and pharmacy standards.
A patient decision checklist to bring to your visit
- Define the goal: What symptom or measurable outcome are we addressing, and what should be evaluated first?
- Compare options: What established treatments or non-drug approaches should we discuss?
- Identify the product: Can you write down the exact ingredient, form, route, and dispensing pharmacy?
- Explain the evidence: Which human findings apply to this proposal, and where are you extrapolating?
- Plan follow-up: What would count as improvement, what would prompt stopping, and whom should I contact with concerns?
- Check understanding: Can I take home a written explanation of the uncertainties and next steps?
Use the checklist to organize a conversation, not to approve a product yourself. If an answer is unclear, ask the clinician or pharmacist to explain it in plain language before making a decision.
Frequently asked questions
Did HHS FDA-approve BPC-157 or the other five peptides?
No. Enforcement discretion does not turn compounded drugs into FDA-approved products. FDA explains the distinction.
Does the policy cover every pharmacy?
No. LegitScript describes qualifying 503A arrangements and explicitly excludes 503B outsourcing facilities from this policy. See the scope explanation.
Are BPC-157 and TB-500 blends covered?
LegitScript’s interpretation excludes combinations with another active ingredient. Do not treat separate-vial co-use as an established workaround. Read its single-API interpretation.
Does an oral route guarantee adequate absorption?
No. The policy calls for documentation for the specific oral formulation in humans. See the oral-bioavailability condition.
Is a certificate of analysis proof a treatment will work?
No. A COA addresses testing questions; clinical benefit is a separate question. Ask what was tested and what was not. Our pharmacy-quality guide explains COAs.
Does this article confirm availability through 1st Optimal?
No specific compound, pharmacy arrangement, or state availability is confirmed here. Ask about current options during your consultation; a policy headline cannot determine your eligibility.
Discuss your next steps with 1st Optimal
1st Optimal is a management services organization offering functional health coaching and facilitating care with contracted licensed medical providers. Medical evaluation and prescribing decisions belong to licensed providers.
Have questions about your symptoms or health goals? Schedule a health consultation with 1st Optimal to discuss next steps. Any medical treatment requires evaluation by a licensed provider; a consultation does not guarantee a prescription.
This article provides general education and is not individualized medical or legal advice.
Sources and update history
- Federal Register: October 30, 2026 notice; filed October 28
- HHS: enforcement discretion policy and Appendices A–B
- LegitScript: November 2, 2026 certification review update
- FDA: Understanding the Risks of Compounded Drugs
